Competition between α- and β-secretase processing of APP at the initial stage defines the subsequent cleavage cascade and spectrum of products, which suggests a potential AD treatment strategy based on β-secretase inhibition and/or α-secretase upregulation [75,76]. Here, APP is linked to Alzheimer disease.